Chronic dopamine replacement therapies in Parkinson’s disease can induce side effects, such as levodopa-induced dyskinesias and impulse control disorders. A dysfunction of inhibitory brain networks has been related to both disorders; however, there is no clear behavioral evidence supporting this hypothesis. We aimed to determine whether PD patients with levodopa-induced dyskinesias show features of increased impulsivity in parallel with altered motor inhibition.
Two matched samples of Parkinson’s disease patients with (n = 14) or without (n = 14) levodopa-induced dyskinesias and a control group (n = 10) participated in the study. All groups were evaluated by the Barratt Impulsiveness Scale-11 to assess impulsivity traits. Furthermore, participants performed a stop signal task to evaluate reactive-motor inhibition and a Go/NoGo task to evaluate proactive-inhibitory control. PD patients were tested both in OFF and ON levodopa medication.
Parkinson’s disease patients with levodopa-induced dyskinesias showed higher impulsivity scores than PD patients without levodopa-induced dyskinesias. Dyskinetic patients presented also delayed stop signal reaction times indicating a worse performance in reactive inhibition. The slowness in inhibiting a motor command correlated with the impulsiveness scores. Furthermore, in the dyskinetic group, a positive correlation was found between stop reaction times and the severity of involuntary movements. Under the effect of levodopa, all patients were faster but dyskinetic patients were significantly less accurate in proactive inhibition.
Inhibitory control is compromised in dyskinetic patients in parallel with increased impulsivity, revealing an impairment of motor and behavioral inhibitory control in Parkinson’s disease patients with levodopa-induced dyskinesias.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Hauser RA (2009) Levodopa: past, present, and future. Eur Neurol 62:1–8
Jiménez-Urbieta H, Gago B, de la Riva P, Delgado-Alvarado M, Marin C, Rodriguez-Oroz MC (2015) Dyskinesias and impulse control disorders in Parkinson’s disease: from pathogenesis to potential therapeutic approaches. Neurosci Biobehav Rev 56:294–314
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22:1379–1389
Marconi R, Lefebvre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y (1994) Levodopa-induced dyskinesias in Parkinson’s disease phenomenology and pathophysiology. Mov Disord 9:2–12
Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47:S2–S9
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidenceof dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group N. Engl J Med 342:1484–1491
Cerasa A, Donzuso G, Morelli M et al (2015) The motor inhibition system in Parkinson’s disease with levodopa-induced dyskinesias. Mov Disord 30:1912–1920
Avanzi M, Baratti M, Cabrini S, Uber E, Brighetti G, Bonfa F (2006) Prevalence of pathological gambling in patients with Parkinson’s disease. Mov Disord 21:2068–2072
Voon V, Hassan K, Zurowski M et al (2006) Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67:1254–1257
Weintraub D, Siderowf AD, Potenza MN et al (2006) Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63:969–973
Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595
Voon V, Rizos A, Chakravartty R et al (2013) Impulse control disorders in Parkinson’s disease: decreased striatal dopamine transporter levels. J Neurol Neurosurg Psychiatry 85:148e152
Evans AH, Strafella AP, Weintraub D, Stacy M (2009) Impulsive and compulsive behaviors in Parkinson’s disease. Mov Disord 24:1561–1570
Weintraub D, David AS, Evans AH, Grant JE, Stacy M (2015) Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord 30:121–127
Brusa L, Pavino V, Massimetti MC, Ceravolo R, Stefani S, Stanzione P (2016) Pathological gambling in Parkinson’s disease patients: dopaminergic medication or personality traits fault? J Neurol Sci 366:167–170
Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ (2006) Punding and dyskinesias. Mov Disord 21:2214–2217
Solla P, Cannas A, Floris GL et al (2011) Behavioral, neuropsychiatric and cognitive disorders in Parkinson’s disease patients with and without motor complications. Prog Neuropsychopharmacol Biol Psychiatry 35:1009–1013
Gauggel S, Rieger M, Feghoff TA (2004) Inhibition of ongoing responses in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:539–544
Obeso JA, Jahanshahi M (2011) Deficits in inhibitory control and conflict resolution on cognitive and motor tasks in Parkinson’s disease. Exp Brain Res 212:371–384
Nombela C, Rittman T, Robbins TW, Rowe JB (2014) Multiple modes of impulsivity in Parkinson’s disease. PLoS One 9:e85747
Aron AR (2011) From reactive to proactive and selective control: developing a richer model for stopping inappropriate responses. Biol Psychiatry 69:e55–e68
Bari A, Robbins TW (2013) Inhibition and impulsivity: behavioral and neural basis of response control. Prog Neurobiol 108:44–79
Verdejo-García A, Lawrence AJ, Clark L (2008) Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev 32:777–810
Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”, a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198
Mahieux F, Michelet D, Manifacier MJ, Boller F, Fermanian J, Guillard A (1995) Mini-mental Parkinson: first validation study of a new bedside test constructed for Parkinson’s disease. Behav Neurol 8:15–22
Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
Defer GL, Widner H, Marié RM, Rémy P, Levivier M (1999) Core assessment program for surgical interventional therapies in Parkinson’s disease (CAPSIT-PD). Mov Disord 14:572–584
Patton JH, Stanford MS, Barratt ES (1995) Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51:768–774
Aron AR, Poldrack RA (2006) Cortical and subcortical contributions to stop signal response inhibition: role of the subthalamic nucleus. J Neurosci 26:2424–2433
Pandey AK, Kamarajan C, Tang Y et al (2012) Neurocognitive deficits in male alcoholics: an ERP/sLORETA analysis of the N2 component in an equal probability Go/NoGo task. Biol Psychol 89:170–182
Picazio S, Veniero D, Ponzo V, Caltagirone C, Gross J, Thut G, Koch G (2014) Prefrontal control over motor cortex cycles at beta frequency during movement inhibition. Curr Biol 24:2940–2945
Picazio S, Ponzo V, Koch G (2016) Cerebellar control on prefrontal-motor connectivity during movement inhibition. Cerebellum 15:680–687
Cerasa A, Koch G, Donzuso G et al (2015) A network centred on the inferior frontal cortex is critically involved in levodopa-induced dyskinesias. Brain 138:414–427
Cerasa A, Koch G, Fasano A, Morgante F (2015) Future scenarios for levodopa-induced dyskinesias in Parkinson’s disease. Front Neurol 6:76
Ponzo V, Picazio S, Benussi A et al (2016) Altered inhibitory interaction among inferior frontal and motor cortex in L-dopa-induced dyskinesias. Mov Disord 31:755–759
Lago-Rodriguez A, Ponzo V, Jenkinson N et al (2016) Paradoxical facilitation after depotentiation protocol can precede dyskinesia onset in early Parkinson’s disease. Exp Brain Res 234:3659–3667
Claassen DO, van den Wildenberg WP, Harrison MB et al (2015) Proficient motor impulse control in Parkinson disease patients with impulsive and compulsive behaviors. Pharmacol Biochem Behav 129:19–25
Obeso I, Wilkinson L, Jahanshahi M (2011) Levodopa medication does not influence motor inhibition or conflict resolution in a conditional stop-signal task in Parkinson’s disease. Exp Brain Res 213:435–445
Eagle DM, Bari A, Robbins TW (2008) The neuropsychopharmacology of action inhibition: cross-species translation of the stop-signal and go/no-go tasks. Psychopharmacology 199:439–456
Eagle DM, Wong JC, Allan ME, Mar AC, Theobald DE, Robbins TW (2011) Contrasting roles for dopamine D1 and D2 receptor subtypes in the dorsomedial striatum but not the nucleus accumbens core during behavioral inhibition in the stop-signal task in rats. J Neurosci 31:7349–7356
Logan GD, Schachar RJ, Tannock R (1997) Impulsivity and inhibitory control. Psychol Sci 8:60–64
Oosterlaan J, Logan GD, Sergeant JA (1998) Response inhibition in AD/HD, CD, comorbid AD/HD + CD, anxious, and control children: a meta-analysis of studies with the stop task. J Child Psychol Psychiatry 39:411–425
Monterosso JR, Aron AR, Cordova X, Xu JS, London ED (2005) Deficits in response inhibition associated with chronic methamphetamine abuse. Drug Alcohol Depend 79:273–277
Krikorian R, Zimmerman ME, Fleck DE (2004) Inhibitory control in obsessive–compulsive disorder. Brain Cogn 54:257–259
Chowdhury NS, Livesey EJ, Blaszczynski A, Harris JA (2017) Pathological gambling and motor impulsivity: a systematic review with meta-analysis. J Gambl Stud 33:1213–1239
Sincere thanks to Gianluigi Rubino, Marilena Minei and to Prof. Fabio Ferlazzo for their essential contribution in reviewing the manuscript.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
The Local Ethics Committee of the IRCCS “Santa Lucia” Foundation according to the Helsinki Declaration approved the study.
Written consent was obtained from all participants.
About this article
Cite this article
Picazio, S., Ponzo, V., Caltagirone, C. et al. Dysfunctional inhibitory control in Parkinson’s disease patients with levodopa-induced dyskinesias. J Neurol 265, 2088–2096 (2018). https://doi.org/10.1007/s00415-018-8945-1
- Parkinson’s disease
- Levodopa-induced dyskinesia
- Motor inhibition
- Stop-signal task